Clinical Trial: Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms

U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07872709) titled 'Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms' on Oct. 07.

Brief Summary: This is a phase II, multicenter, open-label study evaluating the feasibility, safety, and efficacy of oral tetrahydrouridine-decitabine (THU-decitabine) in patients with advanced myeloproliferative neoplasms (MPN).

Study Start Date: Jan., 2027

Study Type: INTERVENTIONAL

Condition: Myelofibrosis MPN - Accelerated or Blast Phase Chric Phase MPN

Intervention: DRUG: Oral THU-decitabine

Combination of Tetrahydrouridine and Decitabine oral treatment. Treatment is ingested weekly without interruption. For convenience ...